Small risk of breast cancer seen with hormone contraceptives
Modern low-dose birth control pills, available since the 1990s, have fewer side effects than the earliest oral contraceptives
Conclusions: Study findings suggest that variation in benefit design of Part D plans accounts for an important share of the large and persisting variability in use of AIs-the preferred oral therapy for breast cancer. PMID: 29223989 [PubMed - in process]
Conclusions: In the absence of a national screening program for breast cancer, the high-risk approach for screening should be considered. Women with the above characteristics should be identified and motivated to seek mammogram regularly to warrant a better outcome. PMID: 29218120 [PubMed]
Elevated cancer risk associated with birth control, Published online: 08 December 2017; doi:10.1038/d41586-017-08403-1Nationwide study finds higher rates of breast cancer with current or former use of oral contraceptives.
Researchers from the University of Santa Maria in Brazil believe the bacteria that cause mouth inflammation enter the circulation via the gums where they go into breast tissue and cause tumours.
By Meera Senthilingam, CNN (CNN) — Birth control can increase a woman’s risk of breast cancer by up to 38%, depending on how long she has taken it, a new study finds. The risk was associated with all forms of hormonal contraception — such as the pill, injections or IUDs — when compared with women who have never used them. Researchers from the University of Copenhagen analyzed data from 1.8 million women under the age of 50 in Denmark. They followed the women for nearly 11 years, on average. The level of breast cancer risk increased the longer a woman had been taking hormonal contraceptives, with the...
A study led by the University of Aberdeen found the combined pill and progestogen-only pill have same risk, as do non-oral products such as the hormone-intrauterine system (IUS).
(King + Company) I-SPY TRIAL for Breast Cancer shows pathological complete response (pCR) predicts event-free/disease-free survival: Findings presented in Oral Presentation at San Antonio Breast Cancer Symposium today by Douglas Yee, MD for Quantum Leap Healthcare Collaborative.
Conclusions: Adverse effects contribute to BCSs decisions to stop OET, yet there has been little investigation of the process through which that occurs. This review serves as a call to action for providers to provide support to BCSs experiencing OET adverse effects and facing decisions related to nonadherence. Implications for Practice: Findings suggest BCSs prescribed OET have unmet decisional needs, and more decisional supports are needed for BCSs experiencing OET adverse effects.
Conclusions: This study shows that adherence assumes different connotations that are mainly influenced by the type of relationship established with health professionals the attention paid to the person, the information received, and the influence that the drug has on the disease. Implications for Practice: It appears that fear has a strong influence on the behaviors involved in taking the therapy. The only way to overcome irrational fear is to improve the patient’s knowledge.
ConclusionThis study met its feasibility endpoints. This novel pragmatic trial approach offers a means of comparing standard of care treatments in a practical and cost-effective manner. The trial will now be expanded to compare rates of FN between the three filgrastim schedules.Trial registrationClinicalTrials.gov: NCT02428114.